Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;10(3):2045894020935289.
doi: 10.1177/2045894020935289. eCollection 2020 Jul-Sep.

Anti-synthetase syndrome-associated pulmonary veno-occlusive disease

Affiliations

Anti-synthetase syndrome-associated pulmonary veno-occlusive disease

Diana Kay et al. Pulm Circ. .

Abstract

Pulmonary arterial hypertension has been reported with a prevalence of 7.9% in patients with anti-synthetase syndrome; however, anti-synthetase syndrome associated with pulmonary veno-occlusive disease (PVOD) has never before been described in the literature. We present a novel case of anti-synthetase syndrome-associated PVOD in a patient who presented with hypoxic respiratory failure associated with right heart failure and was diagnosed with anti-synthetase syndrome based on his autoimmune serology and pre-capillary pulmonary hypertension on right heart catheterization. He was initiated on pulmonary arterial hypertension therapy, but with escalating dose of parenteral epoprostenol, experienced acute clinical worsening with chest imaging concerning for PVOD that was confirmed on autopsy. Anti-synthetase syndrome can be associated with PVOD, and it should be suspected in patients who have evidence of pre-capillary pulmonary hypertension and who deteriorate with the initiation of pulmonary hypertension-specific therapy.

Keywords: anti-synthetase syndrome; pulmonary arterial hypertension; pulmonary veno-occlusive disease.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Axial chest CT images on admission (a), and after initiation of parenteral epoprostenol therapy showing extensive ground glass opacities, smooth septal thickening, and bilateral pleural effusions (b).
Fig. 2.
Fig. 2.
Hematoxylin and eosin (a) and elastin (b) stains showing an occluded pulmonary vein (at left) with reduplication of the elastic lamina surrounded by dilated capillaries. The edge of an arteriole is shown (bottom right) with focal fibrotic disruption of the internal elastic lamina.

References

    1. Wilkins MR, Aman J, Harbaum L, et al. Recent advances in pulmonary arterial hypertension. F1000Res 2018; 7: >F1000 Faculty Rev-1128.
    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. - PMC - PubMed
    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed) 2016; 69: 177. - PubMed
    1. Holcomb BW, Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671–1679. - PubMed
    1. Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42: 1271–1282. - PubMed

LinkOut - more resources